Aarti Pharmalabs
Market cap ₹9,189 Cr
- P/E
- 35.82
- Day range
- ₹992.45 – ₹1,028.95
- 52-week range
- ₹585.00 – ₹1,047.25
- Volume
- 5.77 L
- Open
- ₹1,007.00
- Prev close
- ₹1,015.90
Latest results · Q2 FY27(consolidated)Revenue ₹610 Cr+45.9%Profit ₹71 Cr+156.0%Margin 11.7%YoY vs the same quarter last year
3 red flags to read up on
- high
Promoters selling in the market
Promoter group sold a net ₹222 Cr on the open market in 90 days · 22 Sept 2026
- medium
Promoter pledge went up
11.98% of promoter shares pledged, up from 11.08% · 30 Sept 2026
- medium
Promoter holding falling
39.66%, down 3.22 pts since 2025-09-30 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
AARTIPHARM in NSE indices and F&O
Research profile
Composite 50 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.8%
- Graham no.
- ₹403.92
- vs Graham
- -60.1%
- ROE ÷ P/B
- 2.1%
- 12-1 mom.
- +14.0%
- Return / vol
- 0.71
- Magic Formula
- #461
- Piotroski
- 4/6
- FCF yield
- -2.0%
- PEG
- 0.23
Appears in 15 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Aarti PharmalabsAARTIPHARM | ₹9,189 Cr | 35.82 | 4.01 | 8.5% | 11.0% | 22.0% | 0.40 | +45.9% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1m agoHeadlines about Aarti Pharmalabs from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 35.3
- EPS (TTM)
- ₹26.81
- Price / Book
- 4.07
- ROE (FY26)
- 8.5%
- ROCE (latest year)
- 11%
- Dividend yield
- 0.35%
Moving averages (NSE)
- 20-day
- ₹917.31
- Price above
- 50-day
- ₹896.6
- Price above
- 200-day
- ₹759.1
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Public
- Promoter
- DII
- FII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 | 610 |
| YoY Sales growth | -5 | — | — | — | — | — | -30 | -9 | -20 | — | — | — |
| Expenses | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 | 475 |
| Operating Profit | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 | 135 |
| OPM % | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% | 22% |
| Other Income | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 | 5 |
| Interest | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 | 15 |
| Depreciation | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 | 31 |
| Profit before tax | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 | 95 |
| Tax % | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% | 25% |
| Net Profit | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 | 71 |
| EPS in Rs | ₹5.82 | ₹7.20 | ₹6.12 | ₹6.03 | ₹8.16 | ₹9.75 | ₹5.46 | ₹3.08 | ₹5.29 | ₹6.74 | ₹8.40 | ₹7.88 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+2 days since Mar 2022
+8 days since Mar 2022
+23 days since Mar 2022
-13 days since Mar 2022
-21 days since Mar 2022
Strengths, risks & growth
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals [1]
Strengths
- Company is expected to give good quarter
Risks
- Stock is trading at 4.08 times its book value
- Promoter holding has decreased over last quarter: -3.20%
- Company has a low return on equity of 11.9% over last 3 years.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- -2%
- TTM
- +13%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- -3%
- TTM
- +9%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +36%
- 1 Year
- +43%
Return on Equity
- 10 Years
- —
- 5 Years
- +13%
- 3 Years
- +12%
- Last Year
- +9%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 43.10% | 43.08% | 42.86% | 39.66% | -3.20 pp |
| FII | 7.69% | 8.39% | 8.17% | 8.16% | -0.01 pp |
| DII | 7.66% | 7.40% | 7.22% | 8.40% | +1.18 pp |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.00 pp |
| Public | 41.54% | 41.10% | 41.74% | 43.78% | +2.04 pp |
Filed with NSE for Sept 2026: promoters 39.66%, public 60.34%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 0.60% (-0.19 pp)- Promoters39.7%
- Foreign institutions8.2%
- Mutual funds0.6%
- Insurance4.8%
- Other domestic institutions3.0%
- Retail25.4%
- Others18.4%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.15% | 0.55% | +0.18 pp |
| UTI Healthcare Fund | 0.15% | 0.91% | +0.18 pp |
| Union Active Momentum Fund | 0.11% | 1.82% | +1.82 pp |
| WOC Pharma and Healthcare Fund | 0.11% | 1.06% | +0.22 pp |
| Unifi Flexi Cap Fund | 0.09% | 3.11% | +1.86 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 45.5%
- Downside volatility
- 41.2%
- Worst 5% of days
- 4.3%
- Average of that tail
- 5.7%
- Max drawdown (1Y)
- 37.0%
- Below its peak
- 0.2%
Against the market
- Beta vs Nifty 50
- 1.12
- Correlation
- 0.33
- Relative strength (3M)
- +13.7%
- ATR (14)
- 4.5%
Return
- Return 1M
- +16.0%
- Return 3M
- +17.6%
- Return 6M
- +44.5%
- Return 1Y
- +32.3%
- vs 200-day average
- +33.5%
Momentum
- RSI (14)
- 66.0
- MACD histogram
- 11.61
- Stochastic %K
- 82.4
- ADX (14)
- 32.3
- +DI / −DI
- 30.2 / 10.3
- Money flow index
- 72.3
Participation
- Delivery (20d avg)
- 42.8%
- vs its 60-day baseline
- -0.2 pts
- Volume vs 20-day
- -0.2σ
- Close vs day's VWAP
- +0.3%
- 52-week position
- 99 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- -₹186 Cr
- FCF yield
- -2.0%
- Cash conversion
- 1.40
- Accruals ratio
- -0.022
- Net debt
- ₹893 Cr
- Net debt / equity
- 0.40
- EV / sales
- 4.67
- PEG
- 0.23
- Capex intensity
- 24.6%
- Revenue CAGR
- 45.9%
- Profit CAGR
- 156.0%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
ARTI RAJENDRA GOGRI Promoter Group · Market Sale | Sell | 1,33,564 | ₹10.9 Cr | 25 Sept 2026 |
Relacion Trusteeship Services Private Limited Promoter · Market Sale | Sell | 3,80,000 | ₹31.1 Cr | 25 Sept 2026 |
Gloire Trusteeship Services Private Limited Promoter Group · Market Sale | Sell | 3,97,500 | ₹32.5 Cr | 25 Sept 2026 |
RAJENDRA VALLABHAJI GOGRI Promoter · Market Sale | Sell | 3,88,725 | ₹31.8 Cr | 25 Sept 2026 |
Gloire Trusteeship Services Private Limited Promoter Group · Market Sale | Sell | 6,24,500 | ₹51.1 Cr | 22 Sept 2026 |
Relacion Trusteeship Services Private Limited Promoter Group · Market Sale | Sell | 6,27,500 | ₹51.4 Cr | 22 Sept 2026 |
Safechem Enterprises Private Limited Promoter Group · Market Sale | Sell | 59,400 | ₹5.2 Cr | 9 Sept 2026 |
Relacion Trusteeship Services Private Limited Promoter Group · Market Sale | Sell | 60,000 | ₹5.2 Cr | 9 Sept 2026 |
Safechem Enterprises Private Limited Promoter Group · Market Sale | Sell | 30,000 | ₹2.6 Cr | 7 Sept 2026 |
Safechem Enterprises Private Limited Promoter Group · Market Sale | Sell | 600 | ₹5.1 L | 31 Aug 2026 |
Safechem Enterprises Private Limited Promoter Group · Market Sale | Sell | 15,000 | ₹1.3 Cr | 19 Aug 2026 |
Safechem Enterprises Private Limited Promoter Group · Market Sale | Sell | 23,482 | ₹2.1 Cr | 18 Aug 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹2.00
Dividend - Rs 2 Per Share
15 Sept 2026ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
16 Feb 2026ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
15 Sept 2025ex-date - dividend₹2.50
Interim Dividend - Rs 2.50 Per Share
14 Feb 2025ex-date - dividendNot available — not reported in this filing
Dividend - Re 1 Per Share
31 Jul 2024ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
16 Feb 2024ex-date
Company announcements
This is to inform you that the Earnings Conference Call for investors and analysts has been scheduled for Thursday, October 28, 2026, at 3:30 p.m. (IST) to discuss the Company's Q2-FY27 ....
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026.
Please find enclosed
Please find enclosed
Please find enclosed
Scrutinizers Report and Voting Result of 7th Annual General Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gloire Trusteeship Services Pvt Ltd & Others
Investor Presentation made at the 7th Annual General Meeting
Proceedings of the 7th Annual General Meeting
Please find enclosed
Please find enclosed
Please find enclosed
Please find enclosed BRSR for FY 2025-26
Filed with BSE (scrip 543748); the last 45 days. Documents open at bseindia.com.
Documents
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Sep 2026Slides
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 9 Oct from crisil
- Rating update · 13 Mar from crisil
- Rating update · 17 Jul 2025 from crisil
- Rating update · 17 Mar 2025 from crisil
- Rating update · 26 Jun 2024 from crisil
- Rating update · 8 May 2024 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 29 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Aarti Pharmalabs: common questions
Answered from the figures on this page.